Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Immune checkpoint inhibitors have significantly improved survival for a variety of malignancies over the past decade, but the costs of these medications have barely changed.An investigation into 11 ...

Merck & Co., Inc. (MRK) reached a new 52-week high, with its stock price climbing to $107.62. This milestone reflects positive investor sentiment and confidence in the company’s performance over the ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 17, the US Food ...

The health reset that began in India after COVID-19 is no longer just about avoiding illness. It has quietly evolved into ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection ...

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and ...

Merck & Co., Inc. (NYSE:MRK) is one of the best affordable stocks with good earnings growth for 2026. On December 19, Merck & ...

For decades, cancer patients have been told that shrinking tumors meant accepting brutal side effects as the price of ...

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

A court in Munich has granted a preliminary injunction that will prevent MSD from distributing the subcutaneous version of its cancer immunotherapy Keytruda in the German market. The verdict is the ...